Systematic review with meta-analysis: long-term outcomes of faecal microbiota transplantation for Clostridium difficile infection
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Clostridium difficile infection is a major cause of nosocomial diarrhoea. AIM: To evaluate long-term (≥90 days) efficacy and safety of faecal microbiota transplantation for C. difficile infection and explore the factors affecting the faecal microbiota transplantation outcomes. METHODS: MEDLINE, the Cochrane Library and EMBASE were searched and only observational studies that utilised faecal microbiota transplantation for C. difficile infection with long-term follow-up duration (≥90 days) were included. Primary cure rate, overall recurrence rate and early (<90 days) and late (≥90 days) recurrence rate were calculated. RESULTS: Eighteen observational studies with 611 patients were included. The primary cure rate was 91.2% (95% confidence interval, CI 86.7-94.8%). The overall recurrence rate was 5.5% (95% CI 2.2-10.3%). The early recurrence rate and late recurrence rate were 2.7% (95% CI 0.7-6.0%) and 1.7% (95% CI 0.4-4.2%) respectively. Most adverse events were expected, short-lived, self-limited and manageable. The association between faecal microbiota transplantation therapy and adverse events such as inflammatory bowel disease flare, infectious disease and autoimmune disease was a concern but remained insignificant. Old age (≥65 years) was identified as a risk factor for after faecal microbiota transplantation therapy. Upper gastrointestinal administration also results in less frequent primary cure. CONCLUSIONS: Faecal microbiota transplantation seems to be a highly effective and robust therapy for recurrent C. difficile infection. However, more quality studies, such as randomised controlled trials and cohort studies with control groups, are needed to confirm its long-term efficacy and safety.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708 · cited 1×
“The landmark randomised controlled trail (RCT) in 2013 reported that the cure rate for recurrent CDI with FMT and lavage was 81% compared to 23% with vancomycin alone and 31% with vancomycin and gut lavage.(16) A recent study also showed significant benefits of FMT compared to vancomycin.”
ResultGuidelines for diagnosis, treatment, and prevention of Clostridium difficile infections
Surawicz, C. M., Brandt, L. J., Binion, D. G., Ananthakrishnan, A. N., Curry, S. R., Gilligan, P. H., McFarland, L. V., Mellow, M., & Zuckerbraun, B. S. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.4 · Cited by 1,645
Treating Clostridium difficile infection with fecal microbiota transplantation
Bakken, J. S., Borody, T., Brandt, L. J., Brill, J. V., Demarco, D. C., Franzos, M. A., Kelly, C., Khoruts, A., Louie, T., Martinelli, L. P., et al. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.08.014 · Cited by 1,003
Kassam, Z., Lee, C. H., Yuan, Y., & Hunt, R. H. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.59 · Cited by 904 · cited 2×
“However, this meta-analysis included studies with short or unknown follow-up durations and analysed the cure rate at inconsistent time point.(18) Moreover, the study did not also calculate the recurrence rate and long-term adverse events of FMT therapy for CDI,(18) which is an important rate for FMT efficacy evaluatio…”
BackgroundMethodBrandt, L. J., Aroniadis, O. C., Mellow, M., Kanatzar, A., Kelly, C., Park, T., Stollman, N., Rohlke, F., & Surawicz, C. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.60 · Cited by 672 · cited 16×
“‘ ’ means unrelated to FMT, ‘+’ means less possibly related to FMT, ‘++’means possibly related to FMT, ‘+++’ means probably related to FMT. Aliment Pharmacol Ther 2016; 43: 445–457 453 ª 2015 John Wiley & Sons Ltd latter might be the main factor in the pathophysiology of recurrent CDI.43, 44 With advances in understan…”
BackgroundMethodInfluentialKelly, C. R., Ihunnah, C., Fischer, M., Khoruts, A., Surawicz, C., Afzali, A., Aroniadis, O., Barto, A., Borody, T., Giovanelli, A., et al. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.133 · Cited by 636
Youngster, I., Sauk, J., Pindar, C., Wilson, R. G., Kaplan, J. L., Smith, M. B., Alm, E. J., Gevers, D., Russell, G. H., & Hohmann, E. L. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu135 · Cited by 467 · cited 3×
“However, a randomised, controlled pilot study concluded that nasogastric tube administration appeared to be as effective as colonscopic administration.(51) However, the number of patients in each group was only 10, indicating a weak study power.”
BackgroundCammarota, G., Ianiro, G., & Gasbarrini, A. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000046 · Cited by 428
Mattila, E., Uusitalo–Seppälä, R., Wuorela, M., Lehtola, L., Nurmi, H., Ristikankare, M., Moilanen, V., Salminen, K., Seppälä, M., Mattila, P. S., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.11.037 · Cited by 371 · cited 7×
“Mattila et al.(11) RCS 70 73 (22–90) 60 3.”
BackgroundMethodInfluentialDe Leon, L. M., Watson, J. B., & Kelly, C. R. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.04.045 · Cited by 215 · cited 2×
“Furthermore, conducting faecal microbial analysis before and after FMT in these patients may help in better understanding of the underlying mechanisms.(57) In addition to the gastrointestinal”
BackgroundMethodRussell, G. H., Kaplan, J. L., Youngster, I., Baril‐Dore, M., Schindelar, L., Hohmann, E., & Winter, H. S. (2014) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000000283 · Cited by 64 · cited 7×
“…al.,2012 Mattila et al.,2012 Kelly et al.,2012 Youngster et al.,2014 Zainah et al.,2014 Macconnachie et al.,2009 Aas et al.,2003 Pathak et al.,2014 Russell et al.,2014 Lee et al.,2014 Hirsch et al.,2015 Aroniadis et al.,2015 Khan et al.,2014 0.5 0.6 0.7 0.8 0.9…”
BackgroundInfluentialVermeire, S., Joossens, M., Verbeke, K., Hildebrand, F., Machiels, K., Van den Broeck, K., Van Assche, G., Rutgeerts, P. J., & Raes, J. (2012) · Gastroenterology · doi:10.1016/s0016-5085(12)61356-0 · Cited by 63
Cited by
An insight into gut microbiota and its functionalities
Adak, A., & Khan, M. R. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2943-4 · Cited by 1,485
Impact of the gut microbiota on inflammation, obesity, and metabolic disease
Boulangé, C. L., Neves, A. L., Chilloux, J., Nicholson, J. K., & Dumas, M.-E. (2016) · Genome Medicine · doi:10.1186/s13073-016-0303-2 · Cited by 1,438
“Fecal transplantation is an efficient way to reshape the gut microbial ecosystem after antibiotic treatment or to help fight intestinal infection with Clostridium difficile and can be used as therapy for inflammatory bowel diseases [69, 70].”
BackgroundCostello, S. P., Hughes, P. A., Waters, O., Bryant, R. V., Vincent, A. D., Blatchford, P., Katsikeros, R., Makanyanga, J., Campaniello, M. A., Mavrangelos, C., et al. (2019) · JAMA · doi:10.1001/jama.2018.20046 · Cited by 842
Quraishi, M. N., Widlak, M., Bhala, N., Moore, D., Price, M., Sharma, N., & Iqbal, T. H. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14201 · Cited by 617
The microbiota–gut–brain axis in obesity
Torres-Fuentes, C., Schellekens, H., Dinan, T. G., & Cryan, J. F. (2017) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(17)30147-4 · Cited by 612
Metadata
- Authors
- Li, Y.-T., Cai, H.-F., Wang, Z.-H., Xu, J., & Fang, J.-Y.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2015-12-14
- Volume
- 43
- Issue
- 4
- Pages
- 445-457
- ISSN
- 0269-2813 (ISSN-L)
- OpenAlex
- W2196441926
- Cited by
- 157
- References
- 12
- FWCI
- 3.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.